New Cancer Vaccine Harnesses COVID-19 Immune Memory to Fight Tumors
The vaccine uses SARS-CoV-2 immune memory to boost tumor-fighting responses and is now moving into a first-in-human sarcoma study.
9 Articles
9 Articles
Some antibodies could prevent the immune system from effectively fighting cancer, while others could slow the progression of the disease, believe international researchers who are interested in the phenomenon as part of a US 25 million project called ATLAS.
Turning COVID-19 immune memory into a powerful new ally against cancer
In a discovery that could redefine the future of cancer immunotherapy, scientists from Celloram Inc., University Hospitals and Case Western Reserve University have developed a novel cancer vaccine platform that transforms the impact of the largest immunological event in modern history—a synchronized mass immune memory generated through SARS-CoV-2 infection and vaccination—into a powerful ally against cancer.
New cancer vaccine harnesses COVID-19 immune memory to fight tumors
In a discovery that could redefine the future of cancer immunotherapy, scientists from Celloram Inc., University Hospitals and Case Western Reserve University have developed a novel cancer vaccine platform that transforms the impact of the largest immunological event in modern history – a synchronized mass immune memory generated through SARS-CoV-2 infection and vaccination – into a powerful ally against cancer.
In 18 out of 20 people at risk, the immune system reacted to the vaccine. Further studies must show whether it prevents cancer.
Some antibodies could prevent the immune system from effectively fighting cancer, while others could slow the progression of the disease, believe international researchers interested in the phenomenon as part of a US$25 million project called ATLAS.
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
